Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $242.00 at Citigroup

Neurocrine Biosciences (NASDAQ:NBIX) had its target price increased by Citigroup from $204.00 to $242.00 in a research note published on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

NBIX has been the topic of a number of other research reports. Canaccord Genuity Group raised their target price on shares of Neurocrine Biosciences from $164.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday. HC Wainwright raised their target price on shares of Neurocrine Biosciences from $192.00 to $215.00 and gave the stock a “buy” rating in a research note on Tuesday. Mizuho raised their target price on shares of Neurocrine Biosciences from $146.00 to $175.00 and gave the stock a “neutral” rating in a research note on Friday, December 12th. Truist Financial decreased their target price on shares of Neurocrine Biosciences from $169.00 to $140.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. Finally, Wedbush raised their target price on shares of Neurocrine Biosciences from $151.00 to $166.00 and gave the stock an “outperform” rating in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $180.70.

Neurocrine Biosciences Stock Down 1.2%

Shares of NASDAQ:NBIX opened at $130.90 on Tuesday. The firm’s 50 day moving average price is $131.46 and its 200-day moving average price is $138.91. Neurocrine Biosciences has a twelve month low of $84.23 and a twelve month high of $160.18. The stock has a market capitalization of $13.14 billion, a PE ratio of 28.09, a price-to-earnings-growth ratio of 0.69 and a beta of 0.35.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Wednesday, February 11th. The company reported $1.88 earnings per share for the quarter, missing the consensus estimate of $2.36 by ($0.48). Neurocrine Biosciences had a return on equity of 16.48% and a net margin of 16.73%.The business had revenue of $805.50 million during the quarter, compared to the consensus estimate of $804.21 million. During the same quarter last year, the company earned $1.69 EPS. Neurocrine Biosciences’s revenue for the quarter was up 28.3% on a year-over-year basis. Analysts expect that Neurocrine Biosciences will post 4.28 earnings per share for the current fiscal year.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, CEO Kyle Gano sold 36,400 shares of the stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $132.70, for a total transaction of $4,830,280.00. Following the completion of the sale, the chief executive officer directly owned 140,407 shares of the company’s stock, valued at $18,632,008.90. This trade represents a 20.59% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 4.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Neurocrine Biosciences

A number of institutional investors have recently added to or reduced their stakes in the stock. AlTi Global Inc. grew its holdings in Neurocrine Biosciences by 1.0% during the 3rd quarter. AlTi Global Inc. now owns 6,828 shares of the company’s stock valued at $959,000 after buying an additional 70 shares in the last quarter. Huntington National Bank grew its holdings in Neurocrine Biosciences by 12.6% during the 4th quarter. Huntington National Bank now owns 678 shares of the company’s stock valued at $96,000 after buying an additional 76 shares in the last quarter. Vanguard Personalized Indexing Management LLC grew its holdings in Neurocrine Biosciences by 0.7% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 11,112 shares of the company’s stock valued at $1,560,000 after buying an additional 77 shares in the last quarter. Perigon Wealth Management LLC grew its holdings in Neurocrine Biosciences by 3.1% during the 4th quarter. Perigon Wealth Management LLC now owns 2,590 shares of the company’s stock valued at $367,000 after buying an additional 78 shares in the last quarter. Finally, Motley Fool Asset Management LLC grew its holdings in Neurocrine Biosciences by 4.8% during the 4th quarter. Motley Fool Asset Management LLC now owns 1,693 shares of the company’s stock valued at $240,000 after buying an additional 78 shares in the last quarter. 92.59% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Acquisition materially expands Neurocrine’s commercial footprint — adds VYKAT XR (first‑and‑only FDA‑approved therapy for hyperphagia in Prader‑Willi syndrome) and pushes the company into endocrinology/rare metabolic diseases, creating a multi‑product commercial platform alongside INGREZZA and CRENESSITY. Neurocrine Grows in Endocrinology, Rare Disease with $2.9B Soleno Buyout
• Positive Sentiment: Analysts reacted by lifting price targets and reiterating buys — multiple firms (Citigroup, Canaccord, HC Wainwright, BofA, Needham, Wedbush) raised targets substantially, signaling upside to consensus estimates and investor confidence in the deal’s revenue potential. Vykat XR Acquisition Unlocks Diversified Growth — TipRanks
• Neutral Sentiment: Market validated Soleno’s value — SLNO shares jumped sharply on the deal, confirming the premium paid by Neurocrine and market willingness to pay for VYKAT XR’s orphan indication. This supports deal rationale but doesn’t guarantee NBIX near‑term earnings upside. Soleno Therapeutics Soars 32% on $2.9B Merger
• Neutral Sentiment: Soleno voluntarily withdrew its European marketing application for VYKAT XR ahead of the takeover — Neurocrine says it will prioritize the U.S. launch. That could accelerate U.S. commercialization focus but delays/forgoes near‑term EU revenue. Soleno withdraws EU rare disease drug application — Reuters
• Negative Sentiment: Shares dropped on deal announcement — investors appear concerned about the price tag ($2.9B cash), near‑term dilution to capital flexibility or execution risks integrating a new therapeutic area while Neurocrine’s pipeline faces a near‑term lull. This immediate negative reaction drove today’s decline. This Pharma Stock Is Surging 40% — Barron’s
• Negative Sentiment: Some analysts caution on execution and orphan market risks — at least one firm (BMO) kept a Hold, highlighting integration and long‑term execution questions that could cap near‑term multiple expansion. Balanced View on Neurocrine — TipRanks

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.